Sangamo Therapeutics Stock Discussion

$Sangamo Therapeutics (SGMO.US)$ St-920 Study Pivotal Data Readout Expected by End of Q2 2025

$Sangamo Therapeutics (SGMO.US)$
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...

$Sangamo Therapeutics (SGMO.US)$ nice movement

$Sangamo Therapeutics (SGMO.US)$ trash going down shit no one intersted in this i think

$Sangamo Therapeutics (SGMO.US)$ something today

$Sangamo Therapeutics (SGMO.US)$ Fabry deal in Q2, these will blow it up

$Sangamo Therapeutics (SGMO.US)$
This licensing agreement materially strengthens Sangamo's financial position through a $18 million upfront payment that significantly bolsters their balance sheet. For context, this single payment represents approximately 14% of Sangamo's entire market capitalization ($128.6 million), making it an exceptionally material transaction.
The deal's structure is particularly advantageous for Sangamo, as it creates asymmetric upside with minimal ongoin...

$Sangamo Therapeutics (SGMO.US)$
Sangamo's licensing deal with Eli Lilly represents a significant value-creation event for the company. The $18 million upfront payment is substantial for Sangamo, representing approximately 14% of their $128.6 million market capitalization. This non-dilutive funding provides immediate capital without shareholder dilution.
The agreement's structure is particularly favorable - Sangamo transfers technology but bears no further development c...

$Sangamo Therapeutics (SGMO.US)$ short too strong

$Sangamo Therapeutics (SGMO.US)$ the news is amazing waiting for the volume